Interactive Effect of Probiotics Supplementation and Weight Loss Diet on Metabolic Syndrome Features in Patients With Coronary Artery Diseases: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial.
Jalal MoludiMohammad AlizadehMaryam BehroozVahid MalekiMir Hossein Seyed MohammadzadAli GolmohammadiPublished in: American journal of lifestyle medicine (2019)
Background. Nutrition and probiotics supplementation are considered as nondrug strategies for the control of coronary artery disease (CAD). The aim of the present study was to investigate the interactive effects of probiotic supplementation and weight loss program on anthropometric and metabolic syndrome (MetS) indices in patients with CAD. Methods. A randomized, double-blind, placebo-controlled trial was performed in 44 overweight CAD patients. All the patients received weight loss program (5% to 10% of initial body weight) throughout the study course. The subjects were randomly assigned into intervention or placebo groups (n = 22, each) and received a probiotic or maltodextrin capsule/day, respectively, for 12 consecutive weeks. Anthropometric and MetS indices were assessed. Results. There was a significant decrease in total cholesterol (-30.7 ± 49.83 vs -5.9 ± 65 mmol/L, P = .043) and low-density lipoprotein cholesterol (-25.64 ± 51.7 vs -5.44 ± 70.1 mg/dL, P = .049) in the probiotic group compared to the placebo group. Other MetS feature indices and blood pressure did not differ significantly within or between groups. Conclusion. Probiotics supplementation improved total cholesterol and low-density lipoprotein cholesterol but had no effect on other lipid profile parameters and anthropometric indices. The weight loss diet plus probiotics supplementations resulted in more favorable decrease of cardiovascular risk factors compared to a weight loss program alone.
Keyphrases
- weight loss
- double blind
- bariatric surgery
- coronary artery disease
- metabolic syndrome
- roux en y gastric bypass
- placebo controlled
- gastric bypass
- cardiovascular risk factors
- end stage renal disease
- coronary artery
- blood pressure
- body weight
- clinical trial
- randomized controlled trial
- peritoneal dialysis
- physical activity
- chronic kidney disease
- weight gain
- glycemic control
- newly diagnosed
- phase iii
- percutaneous coronary intervention
- type diabetes
- squamous cell carcinoma
- obese patients
- quality improvement
- pulmonary artery
- deep learning
- cardiovascular disease
- atrial fibrillation
- adipose tissue
- heart rate
- gestational age
- open label
- low density lipoprotein
- radiation therapy
- phase ii study